In the present work we have investigated the Introduction possible relationship(s) between these various Degranulation of mast cells occurs during inhibitors/antagonists and the co-administration ischaemia/reperfusion injury in both the rat of L-NAME. The study has focused on mast cell mesentery and small intestine, 2 and it can be degranulation in the presence of such agents. enhanced by prior administration of N-nitro--Two methods have been used involving, firstly, arginine methyl ester (L-NAME), a NO-synthase mast cells in situ in rat omental milky spots inhibitor, or it can be inhibited by prior adminis-(OMCs) and, secondly, mast cells isolated from tration of sodium nitroprusside (SNP), an NO the rat by peritoneal lavage (PMCs).
donor. Epithelial permeability to 51Cr in rat small intestine is also increased by L-NAME and Methods this is associated with mucosal mast cell degranulation. We have shown recently 4 that the LOmental mast cells.. Female rats weighing about NAME-induced increase in microvascular perme250g were killed by inhalation of chloroform ability to injected colloidal carbon in the rat vapour. After opening the abdomen with a small intestine is prevented by pre-treatment with midline incision followed by a lateral subcostal cyproheptadine, a mixed histamine and 5-hydroxy-incision, the lesser omenmm was quickly tryptamine (Fig. 2) . Of these antagonists, however, only indomethacin ( Fig. 1 ) gave significant protection against the disappearance of pink/magentastained OMCs in NS-treated omenta during incubation at 37C, and this was accompanied by a significant increase in the M/DB ratio (to 10.5 _ _ _ 0.9). There was also a significant increase in the M/DB ratio after pre-treatment with SNP (to 12.6 _ _ _ 1.0), but with this drug the increase in the number of metachromatically stained OMCs per milky spot did not reach a conventionai level of statistical significance (Fig. 1) . Pre-treatment of the omentum with NDGA (3 or 30 l.tM) did not reduce the effects of L-NAME significantly (Fig.  2) . In contrast, pre-treatment with BN52021 (10 l.tM) significantly reduced the degranulating effects of PAF (Fig. 3) , whereas a lower concentration (1 l.tM) was not significantly effective. Pre-treatment of the omentum with BZI (50 l.tM) had no effect on the response to PAF. Pre-treatment with BN52021 (10 l.tM), however, significantly reduced the degranulating effects of U46619 (Fig. 3) .
PMCs responded to the addition of PMXB, PAF or U46619 with a significant increase in histamine release (Fig. 4) . SNP, on the other hand, significantly decreased the release of histamine from PMCs (Fig. 4) . In contrast to its mast celldegranulating effect in OMCs (see above), L-NAME exerted no significant effect on the release of histamine from PMCs (Fig. 4) . However, pretreatment of PMCs with BN52021 (10 l.tM) significantl attenuated the histamine-releasing effect of PAF, but not that of U46619 (Fig. 4) . In the presence of L-NAME (100 l.tM) histamine release in response to incubation with PAF or U46619 was increased but only slightly (Fig. 4) both anti-inflammatory and pro-inflammatory effects, depending upon the circumstances. 7'18 In acute gastrointestinal injury there is substantial evidence to su&gest that NO has an anti-inflammatory effect, whereas a pro-inflammatory effect is sometimes more evident during inflammation occurring elsewhere in the body. 8 It has been shown previously that administration of L-NAME, which would be expected to have inhibited NO-synthase, caused leakage of albumin and of injected colloidal carboff' from rat small intestines and mesentery that apparently was due to a release of certain mast cell-derived amines. In the present experiments the application of L-NAME caused degranulation of OMCs in the milky spots. In contrast, pre-treatment with SNP, an NO donor, counteracted this degranulation (Fig. 2) , suggesting that where OMCs are concerned, both exogenous and endogenous NO can be protective. However, in which of the various omental cell type(s) the synthesis of NO was actually being blocked by added L-NAME remains unknown. In contrast, L-NAME did not increase histamine release from PMCs (Fig. 4) . have too low a cytoplasmic calcium ion concentration to permit activation of the constitutive form of NO-synthase. If so, then L-NAME would have no enzyme activity to inhibit. However, under certain circumstances, such as during stirring or incubation with lipopolysaccharide, PMCs in vitro do respond to treatment with L-NAME or other NO-synthase inhibitors with an enhanced release of histamine. 9 In the present experiments, however, L-NAME only slightly augmented the release of histamine that was produced in PMCs by adding PAF or U46619 (Fig. 4) . The reasons for these discrepancies are presently unknown. Successful antagonism of the degranulating effect of L-NAME on OMCs by pre-incubation with indomethacin, BZI, or BN52021 (Fig. 2) suggests that such degranulation may have been in response to the release of endogenous thromboxane A2 (TXA2) and PAF; but from which of the many cell types to be found within the omentum this release occurs is unknown. It is possible that different cell types may be responsible for secretion of the two agents. Since 21 whereas mucosal mast cells were not. 21 However, we are aware that NDGA, unlike BW A137C, has non-specific antioxidant properties. This might account for its lack of effect in the present experiments.
The protective effect of indomethacin on omental mast cells (Fig. 2) 
